miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib

Leukemia. 2015 May;29(5):1210-3. doi: 10.1038/leu.2014.344. Epub 2014 Dec 9.

Authors

D Guinn¹, A S Ruppert², K Maddocks², S Jaglowski², A Gordon², T S Lin³, R Larson⁴, G Marcucci², E Hertlein², J Woyach², A J Johnson⁵, J C Byrd⁵

Affiliations

¹ 1] Biomedical Sciences Graduate Program, College of Medicine, The Ohio State University, Columbus, OH, USA [2] Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
² Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
³ Oncology Research and Development, GlaxoSmithKline, Philadelphia, PA, USA.
⁴ Department of Medicine, University of Chicago, Chicago, IL, USA.
⁵ 1] Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Alemtuzumab
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Disease Progression
Disease-Free Survival
Gene Expression Regulation, Leukemic
Humans
Immunotherapy / methods
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
MicroRNAs / metabolism*
Multivariate Analysis
Piperidines
Protein-Tyrosine Kinases / metabolism*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Rituximab
Treatment Outcome
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
MIRN155 microRNA, human
MicroRNAs
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Alemtuzumab
Rituximab
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Vidarabine
Adenine
fludarabine

Grants and funding